The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Open accessAbstract
Persistent antiphospholipid (aPL) antibodies are occasionally found in subjects without prior history of thromboembolic events (TEs), raising the dilemma of whether to initiate or not a primary thromboprophylaxis. A first TE is considered rare in aPL carriers, but previous studies did not consider the aPL profile nor was the test positivity confirmed in a reference laboratory. In this study, 104 subjects with high-risk aPL profile (positive lupus anticoagulant, anticardiolipin, and anti-β2–glycoprotein I antibodies, triple positivity) confirmed in a reference laboratory, were followed up for a mean of 4.5 years. There were 25 first TEs (5.3% per year): the cumulative incidence after 10 years was 37.1% (95% confidence interval [CI], 19.9%-54.3%). On multivariate analysis, male sex (hazard ratio = 4.4; 95% CI, 1.5-13.1, P = .007) and risk factors for venous thromboembolism (hazard ratio = 3.3; 95% CI, 1.3-8.5, P = .01) were independent predictors for TEs. Aspirin did not significantly affect the incidence of TE. In conclusion, the occurrence of a first TE in carriers of high-risk aPL profile is considerable; it is more frequent among male subjects and in the presence of additional risk factors for venous TE. These data can help in the decision to initiate primary thromboprophylaxis in these subjects.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In 104 asymptomatic carriers of triple-positive antiphospholipid antibodies confirmed in a reference laboratory, first thromboembolic events occurred at 5.3% per year, with a 10-year cumulative incidence of 37.1%. Male sex and venous thromboembolism risk factors independently predicted events, whereas aspirin did not significantly reduce them.
Key findings
- During 469 patient-years of follow-up, there were 25 first thromboembolic events (5.3% per year); cumulative incidence was 9.8% (95% CI, 3.7%-15.9%) at 2 years, 27.3% (95% CI, 17.1%-37.5%) at 5 years, and 37.1% (95% CI, 19.9%-54.3%) at 10 years.
- On multivariate analysis, independent predictors of thromboembolism were male sex (hazard ratio 4.4; 95% CI, 1.5-13.1; P = .007) and presence of risk factors for venous thromboembolism (hazard ratio 3.3; 95% CI, 1.3-8.5; P = .01).
- Aspirin prophylaxis did not significantly affect thromboembolic events on multivariate analysis (hazard ratio 0.5; 95% CI, 0.2-1.5; P = .2); it was close to significance on univariate analysis but did not achieve statistical significance.
- Among the 25 events, there were 12 arterial and 11 venous thromboembolic events, 1 right atrial thrombosis, and 1 renal thrombotic microangiopathy.
Methods
- Multicenter prospective cohort of 104 subjects with high-risk antiphospholipid antibody profile (triple positivity: lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies) on 2 occasions at least 12 weeks apart, without clinical features of antiphospholipid syndrome; triple positivity was confirmed in a reference laboratory. Mean age was 45 years, 79% were female, and mean follow-up was 4.5 years.
- Subjects were seen annually or earlier as clinically indicated; no long-term anticoagulant treatment was prescribed, and short-term low-molecular-weight heparin was given in high-risk thromboembolism scenarios. Data collected included demographic, laboratory, and clinical variables, autoimmune disease, arterial and venous risk factors, and aspirin treatment.
- Kaplan-Meier survival analysis estimated cumulative incidence of thromboembolism; Cox regression survival analysis identified predictors among demographic factors, autoimmune diseases, anticardiolipin isotype, arterial and venous risk factors, and aspirin treatment. Statistical significance was set at P < .05; analyses used SPSS.
Limitations
- The paper does not include a formal limitations section. It states that larger clinical trials are definitely needed to test hypotheses about aspirin and hydroxychloroquine.
- Evident from the text: treatment with aspirin was observational rather than randomized, so confounding by indication cannot be excluded; the cohort had 104 subjects and 25 events, yielding wide confidence intervals for some estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Own result · 7 No full text of the sources · 4 Own interpretation · 3 Own method · 2 Partly supported · 1 Supported so far · 1 Couldn’t confirm · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“that (1.36%) of 125 single aPL positive carriers with a mean age of 41 years (data taken by a recently published study by our group), 15”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Could not verifycites [15] Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study., Ann Rheum Dis sourceExperimental — accuracy not yet measured
The Results and Discussion report an annual thrombosis incidence of 1.86 per 100 patients for the full cohort of 258 aPL carriers. Searches for 125 single-positive carriers and a 1.36% annual rate found no passage reporting that subgroup rate; the overall rate does not establish or contradict it. (LLM, conf=0.73)
plainn = 125- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the higher incidence of TEs recorded in this study may be related to the selection of high-risk aPL-positive population”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Partly supportedcites [15] Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study., Ann Rheum Dis sourceExperimental — accuracy not yet measured
The Analysis of risk factors for thrombosis identifies hypertension and lupus anticoagulant as independent predictors of thrombotic events, supporting the premise that risk profile matters. The Discussion describes this source paper’s own event rate as low and similar to other studies; it does not assess whether selection of a high-risk population explains the higher incidence in the citing study. Page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [16] Mok, 2005, Incidence and risk factors of thromboembolism systemic lupus erythematosus: a comparison of three ethnic groups., Arthritis Rheum source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 18 patients treated with hydroxychloroquine, 2 (11%) had a first TE in the follow-up period.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“male sex (hazard ratio ϭ 4.4; 95% CI, 1.5-13.1,P ϭ .007)and the presence of factors predisposing to VTE (hazard ratio ϭ 3.3; 95% CI, 1.3-8.5,P ϭ .01)were found to be independent predictors for clinical events”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plaincorrelationaln = 25 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Aspirin prophylaxis was close to significance in reducing events on univariate analysis but did not achieve statistical significance on multivariate analysis (hazard ratio ϭ 0.5; 95% CI, 0.2-1.5,P ϭ .2)”
- Also stated in: § Abstract · plain
“As-pirin did not significantly affect the incidence of TE.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“27.3% (95% CI, 17.1%-37.5%)after 5 years”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“male sex (hazard ratio ϭ 4.4; 95% CI, 1.5-13.1,P ϭ .007)and the presence of factors predisposing to VTE (hazard ratio ϭ 3.3; 95% CI, 1.3-8.5,P ϭ .01)were found to be independent predictors for clinical events”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plaincorrelationaln = 25 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the cumulative incidence after 10 years was 37.1% (95% confidence interval [CI], 19.9%-54.3%)”
- Also stated in: § Results · plain
“and 37.1% (95% CI, 19.9%-54.3%)after 10 years (Figure 1).”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, 104 subjects with high-risk aPL profile (positive lupus anticoagulant, anticardiolipin, and anti- 2 -glycoprotein I antibodies, triple positivity) confirmed in a reference laboratory, were followed up for a mean of 4.5 years.There were 25 first TEs (5.3% per year)”
- Also stated in: § Results · plain
“During a total follow-up of 469 years, there were 25 TEs (5.3% per year).”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative incidence of TEs was 9.8% (95% confidence interval [CI], 3.7%-15.9%)after 2 years”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 3
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the annual rate (ϳ 0.4%) of first cardiovascular event (including VTE) in normal white population at 35 to 55 years of age, 14”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Partly supportedcites [14] Roger, 2011, Heart disease and stroke statistics: 2011 update. A report from the American Heart Association., Circulation sourceExperimental — accuracy not yet measured
The Cardiovascular Diseases > Incidence section reports 3 first cardiovascular events per 1,000 men annually at ages 35–44, which is close to the claimed 0.4%. It does not give a single rate for a healthy white population aged 35–55. The Venous Thromboembolism > Incidence section reports VTE separately, not as part of that first-event rate; page numbers were not supplied. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“triple positivity (all 3 tests positive) is associated with thrombosis and identifies high-risk patients with aPL syndrome (APS).6,7”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Introduction
What the sources say
- Not checked — no full text of the sourcecites [6] Pengo, 2005, Antibody profiles for the diagnosis of antiphospholipid syndrome., Thromb Haemost source
- Supportedcites [7] Pengo, 2009, Clinical course of high risk patients diagnosed with antiphospholipid syndrome (APS)., J Thromb Haemost source
The Discussion states that patients positive on all three laboratory tests are at higher risk of thrombosis. The Introduction reports a marked association between multiple positivity and thromboembolic events, and the Discussion describes the triple-positive APS cohort as high-risk. Page numbers are not provided in our copy. (LLM, conf=0.93)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Venous thromboembolism (VTE) was diagnosed by compression ultrasonography or venography in case of deep vein thrombosis, and spiral tomography, ventilation-perfusion lung scan, or pulmonary angiography in case of pulmonary embolism.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Outcome events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data can help in the decision to initiate primary thromboprophylaxis in these subjects.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Rests on an assumption: The clinical course of persons carrying a high-risk antiphospholipid antibody profile (triple positivity) is not known.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it is more frequent among male subjects and in the presence of additional risk factors for venous TE”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“That male sex is related to a higher risk for recurrence of VTE among patients with unprovoked deep vein thrombosis is not new.25”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] McRae, 2006, Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis., Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was approved by the local ethics committee of each Thrombosis Center.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“plasma from patients of each center was retested in a reference laboratory (Padua Thrombosis Center).Final inclusion in the cohort required confirmation of LA positivity as well as aCL and anti- 2 GPI antibody positivity (values in the upper 99th percentile of 40 healthy subjects) for the same isotype.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
plainn = 40- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper relies on this without support.
The clinical course of persons carrying a high-risk antiphospholipid antibody profile (triple positivity) is not known.
“The clinical course in persons with high-risk aPL antibody profile (triple positivity) is not known, casting a shadow on the need for primary prophylaxis to avoid TEs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“aPL profiling also involves consideration of antibody titers since higher titers are associated with higher risk [7,8,30,31].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients positive for the combination of LAC, antiβ 2GPI, and anti-CL antibodies,theso-called triple-positive patients, exhibit a high risk for developing a first thrombotic event and recurrence of thrombosis. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“andpatientspositiveforallthree aPLs are identified as individuals at high risk for a first clinical event and for recurrence. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note is that many studies on triple positivity merely report patients as being positive for LA without assessing dRVVT and APTT results separately [10,[23][24][25][26][27][28][29], or even use only 1 assay [7,8,12].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“it has been demonstrated that asymptomatic persistent carriers of LA and of the other antiphospholipid antibodies have a higher risk of future thromboembolic events [11,12].”
From Lupus Anticoagulant Detection under the Magnifying Glass (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, persistent aPL positivity can also be found in the absence of clinical criteria of APS in patients called 'aPL carriers,' raising the dilemma of initiating or not a primary thromboprophylaxis. 19,20”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
“IgM aCL, GPL units (mean Ϯ SD) 1.42 Ϯ 0.3”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
“The predominant isotype was considered M when IgM aCL value expressed as MPL units exceeded the IgG aCL value (expressed as GPL units).”
Citations
Cites
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Update of the guidelines for lupus anticoagulant detection
PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03555.x · Cited by 1,197
Self-citationGalli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Self-citationErkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401
Antibody profiles for the diagnosis of antiphospholipid syndrome
Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., & Pengo, V. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0839 · Cited by 318
Self-citationEffect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.
McRae, S., Tran, H., Schulman, S., Ginsberg, J., & Kearon, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69110-1 · Cited by 289
Mok, C. C., Tang, S. S. K., To, C. H., & Petri, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21224 · Cited by 237
(2004) · PubMed · Cited by 218
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis
DE GROOT, P. G., LUTTERS, B., DERKSEN, R. H. W. M., LISMAN, T., MEIJERS, J. C. M., & ROSENDAAL, F. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01485.x · Cited by 205
Cited by
Sorted by citations
Items 101–200 of 462
Saraiva, S. D. S., Custódio, I., Mazetto, B. D. M., Colella, M. P., Paula, E. V. D., Appenzeller, S., Annichino-Bizzachi, J., & Orsi, F. A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.10.029 · Cited by 40
The antiphospholipid syndrome – often overlooked cause of vascular occlusions?
Svenungsson, E., & Antovič, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13022 · Cited by 39
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke
Mittal, P., Quattrocchi, G., Tohidi‐Esfahani, I., Sayar, Z., Chandratheva, A., & Cohen, H. (2022) · International Journal of Stroke · doi:10.1177/17474930221150349 · Cited by 41
Pediatric Antiphospholipid Syndrome
Aguiar, C. L., Soybilgic, A., Avčin, T., & Myones, B. L. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0504-5 · Cited by 39
Tonello, M., Mattia, E., Favarò, M., Ross, T. D., Calligaro, A., Salvan, E., Hoxha, A., Fedrigo, M., & Ruffatti, A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.03.006 · Cited by 38
Self-citationAPS - Diagnostics and challenges for the future
Pengo, V., Bison, E., Zoppellaro, G., Jose, S. P., Denas, G., Hoxha, A., Ruffatti, A., & Banzato, A. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.028 · Cited by 37
Self-citationLaboratory Diagnostics of Antiphospholipid Syndrome
Bison, E., Denas, G., Jose, S., Zoppellaro, G., Banzato, A., & Pengo, V. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1601331 · Cited by 37
Self-citationZuily, S., de Laat, B., Guillemin, F., Kelchtermans, H., Magy-Bertrand, N., Desmurs‐Clavel, H., Lambert, M., Poindron, V., de Maistre, E., Dufrost, V., et al. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa072 · Cited by 38
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 37
Self-citationKotzen, E., Roy, S., & Jain, K. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.012 · Cited by 40
Antiphospholipid syndrome: a clinical perspective
Zuo, Y., Shi, H., Li, C., & Knight, J. S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000705 · Cited by 39
“[50] Pengo et al[51] conducted a prospective observation of 179 asymptomatic isolated persistent LA carriers (23% on primary prophylaxis) with a total follow up of 552 patient-years.”
BackgroundTesting for antiphospholipid antibodies: Advances and best practices
Devreese, K. M. J. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13195 · Cited by 39
Yin, D., de Groot, P. G., Ninivaggi, M., Devreese, K. M. J., & de Laat, B. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1344-4271 · Cited by 36
Management of Non-criteria Manifestations in Antiphospholipid Syndrome
Xourgia, E., & Tektonidou, M. G. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00935-2 · Cited by 38
Sciascia, S., Radin, M., Cecchi, I., Bertolaccini, M. L., Bertero, M. T., Rubini, E., Vaccarino, A., Bazzan, M., Giachino, O., Baldovino, S., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/kez596 · Cited by 35
Svenungsson, E., Gustafsson, J. T., Grosso, G., Rossides, M., Gunnarsson, I., Jensen‐Urstad, K., Larsson, A. O., Ekdahl, K. N., Nilsson, B., Bengtsson, A. A., et al. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa092 · Cited by 35
Vanoverschelde, L., Kelchtermans, H., Musial, J., de Laat, B., & Devreese, K. M. J. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12207 · Cited by 33
Ruffatti, A., Silvestro, G. D., Marson, P., Tonello, M., Calligaro, A., Favarò, M., Ross, T. D., Hoxha, A., Mattia, E., & Pengo, V. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.001 · Cited by 35
Self-citationAdditional laboratory tests to improve on the diagnosis of antiphospholipid syndrome
Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14896 · Cited by 34
Self-citationHow to Interpret Antiphospholipid Laboratory Tests
Devreese, K. M. J. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00916-5 · Cited by 36
Clinical causes and treatment of the thrombotic storm
Ortel, T. L., Kitchens, C. S., Erkan, D., Brandão, L. R., Hahn, S. E., James, A., Kulkarni, R., Manco‐Johnson, M. J., Pericak‐Vance, M. A., & Vance, J. M. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.56 · Cited by 34
Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices
Skeith, L., & Bates, S. M. (2024) · Hematology · doi:10.1182/hematology.2024000591 · Cited by 41
Mondejar, R., Rodríguez, C. G., de Miera, F. J. T., Madrid, E. M., Zohoury, N., Mähler, M., Losquiño, I. R., & Fabiani, F. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.047 · Cited by 33
Pastori, D., Bucci, T., Triggiani, M., Ames, P. R. J., Parrotto, S., Violi, F., Pignatelli, P., & Farcomeni, A. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.005 · Cited by 33
Sciascia, S., Roccatello, D., Bertero, M. T., Simone, D. D., Cosseddu, D., Vaccarino, A., Bazzan, M., Rossi, D., Garcia-Fernandez, C., Ceberio, L., et al. (2012) · Inflammation Research · doi:10.1007/s00011-012-0468-0 · Cited by 33
“It is now widely recognized that multiple positivity in tests exploring the presence of aPL [28, 29] and, notably, triple positivity is associated with thrombosis and identifies high-risk patients with APS [30, 31].”
BackgroundTreatment of antiphospholipid syndrome
Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Menegatti, E., Roccatello, D., & Sciascia, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108597 · Cited by 32
Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio
Amory, C. F., Levine, S. R., Brey, R. L., Gebregziabher, M., Tuhrim, S., Tilley, B. C., Simpson, A.-C. C., Sacco, R. L., Mohr, J. P., & Collaborators, F. T. A.-W. (2015) · Cerebrovascular Diseases · doi:10.1159/000441362 · Cited by 31
Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation
Forastiero, R. R. (2014) · Lupus · doi:10.1177/0961203314531635 · Cited by 32
D’Angelo, C., Franch, O., Fernández-Paredes, L., Oreja‐Guevara, C., Núñez-Beltrán, M., Comins‐Boo, A., Reale, M., & Sánchez‐Ramón, S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00107 · Cited by 33
“Additional factors or a ‘‘second hit,’’ mediated by innate immunity, would be necessary to trigger the pathogenesis of the disease in the presence of autoantibodies, according to the current accepted theory (Pengo et al., 2011).”
BackgroundJiang, D., Lim, W., Crowther, M. A., & Garcia, D. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005205 · Cited by 34
“3% per year.(52) By contrast, although anti-B2GPI is often cited as the most pathogenically relevant of the aPLs, we identified only 1 study in which the association between anti-B2GPI and thrombotic outcomes was independent of LA and aCL positivity.”
BackgroundDiagnosis and treatment of antiphospholipid syndrome in childhood: A review
Rumsey, D. G., Myones, B. L., & Massicotte, P. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.02.009 · Cited by 30
Recent developments in our understanding of the antiphospholipid syndrome
de Groot, P. G., Meijers, J. C. M., & Urbanus, R. T. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01414.x · Cited by 31
Yin, D., Chayouâ, W., Kelchtermans, H., de Groot, P. G., Moore, G. W., Gris, J., Zuily, S., Musiał, J., de Laat, B., & Devreese, K. M. J. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14682 · Cited by 31
Baker, S. A., Jin, J., Pfaffroth, C., Vu, T., & Zehnder, J. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12472 · Cited by 30
How I diagnose and treat antiphospholipid syndrome in pregnancy
Branch, D. W., & Lim, M. Y. (2023) · Blood · doi:10.1182/blood.2023020727 · Cited by 32
Laboratory methods to detect antiphospholipid antibodies
Krilis, S. A., & Giannakopoulos, B. (2014) · Hematology · doi:10.1182/asheducation-2014.1.321 · Cited by 30
Beyond the “syndrome”: Antiphospholipid antibodies as risk factors
Andréoli, L., & Tincani, A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33341 · Cited by 29
Laboratory testing for antiphospholipid syndrome
Pengo, V., Banzato, A., Bison, E., Denas, G., Zoppellaro, G., Bracco, A., Jose, S. P., Hoxha, A., & Ruffatti, A. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12507 · Cited by 29
Self-citationAgmon‐Levin, N., Volkov, I., Seguro, L., Leon, E. P., Kovács, L., Roggenbuck, D., Schierack, P., Gilburd, B., Doria, A., Tektonidou, M. G., et al. (2020) · Autoimmunity Highlights · doi:10.1186/s13317-020-00131-3 · Cited by 31
Dilemmas in the diagnosis and management of antiphospholipid syndrome
Manning, J. E., & Arachchillage, D. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.027 · Cited by 34
Diagnosis and therapy of antiphospholipid syndrome
Pengo, V., Denas, G., Jose, S. P., Zoppellaro, G., Bison, E., Banzato, A., Hoxha, A., & Ruffatti, A. (2015) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3051 · Cited by 28
Self-citationBazzan, M., Vaccarino, A., Stella, S., Bertero, M., CARIGNOLA, R., Montaruli, B., Roccatello, D., & Shoenfeld, Y. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.11.007 · Cited by 28
“APS patients with triple positivity, as well as asymptomatic patients with triple positivity are at higher risk of thrombosis and thrombotic recurrences [9,10].”
BackgroundTesting for Lupus Anticoagulants
Moore, G. W. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1744363 · Cited by 30
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?
Mormile, I., Granata, F., Punziano, A., de Paulis, A., & Rossi, F. W. (2021) · Biomedicines · doi:10.3390/biomedicines9020132 · Cited by 28
“The triple-positive population of LA, aCL, and anti-β2GPI has been regarded as the highest risk group for TEs and poor neonatal outcomes [16,17].”
BackgroundJiang, H., Wang, C.-H., Jiang, N., Li, J., Wu, C., Wang, Q., Li, M., Tian, X., Zhao, J., Zhao, Y., et al. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02515-w · Cited by 27
“This is consistent with previous studies, in which triple aPL positivity could be a risk factor of thrombotic events [20].”
ResultMarchetti, T., Ribi, C., Perneger, T., Trendelenburg, M., Huynh‐Do, U., de Moerloose, P., & Chizzolini, C. (2018) · Rheumatology · doi:10.1093/rheumatology/key095 · Cited by 28
Grimaud, F., Yelnik, C., de Chambrun, M. P., Amoura, Z., Arnaud, L., Costedoat-Chalumeau, N., HACHULLA, E., Lambert, M., Roriz, M., Sibilia, J., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key437 · Cited by 27
Habe, K., Wada, H., Matsumoto, T., Ohishi, K., Ikejiri, M., Matsubara, K., Morioka, T., Kamimoto, Y., Ikeda, T., Katayama, N., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5536 · Cited by 26
“The relationship between aPLs and THEs has been previously reported, suggesting that the risk of THE increases as the number of positive aPLs increases (20-22).”
BackgroundCáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 26
Foret, T., Dufrost, V., du Mont, L. S., et al. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab853 · Cited by 26
Clinical Management of Thrombotic Antiphospholipid Syndrome
Tumian, N. R., & Hunt, B. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030735 · Cited by 45
“Male sex [58], smoking [60,61], hypertension [59], and triple positive aPL [61] were among the independent risk factors for thrombosis.”
BackgroundAnticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Blood · doi:10.1182/blood-2018-05-848697 · Cited by 26
“The risk of initial thrombosis is higher when multiple APLA test results are positive and may be as high as 5% per year and 37% after 10 years for individuals with triple-positive results (positive LAC, aCL, and ab2GP1 antibodies).(22,23)”
BackgroundTanimura, K., Saito, S., Nakatsuka, M., Nagamatsu, T., Fujii, T., Fukui, A., Deguchi, M., Sasagawa, Y., Arase, N., Arase, H., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41410 · Cited by 25
Laurent, C., Ricard, L., Nguyen, Y., Boffa, J. J., Rondeau, É., Gerotziafas, G., Elalamy, I., Deriaz, S., MOREUIL, C. D., Planche, V., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002534 · Cited by 28
“21 Only one study previously assessed the risk factors of relapse, and found male sex and combined risk factors for deep venous thrombosis (DVT) (oestrogen, immobilisation, pregnancy, neoplasia and DVT family history) predictive for DVT.”
BackgroundMethodThe chequered history of the antiphospholipid syndrome
Arachchillage, D. J., & Greaves, M. (2014) · British Journal of Haematology · doi:10.1111/bjh.12848 · Cited by 25
“Aspirin did not significantly affect the incidence of thromboembolic events (Pengo et al, 2011).”
BackgroundMeroni, P. L., & Borghi, M. O. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0066 · Cited by 26
“In addition, the positivity for two or three of these tests confers a higher risk than the positivity for a single test only [30].”
BackgroundGkrouzman, E., Sevim, E., Finik, J., Andrade, D., Pengo, V., Sciascia, S., Tektonidou, M. G., Ugarte, A., Chighizola, C. B., Belmont, H. M., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.200513 · Cited by 24
“Triple aPL positivity 10,11 or LAC positivity 12 is known to confer a higher risk for aPL-related clinical events compared to aCL and anti–β 2 -GPI positivity.”
BackgroundSelf-citationZuo, Y., Barbhaiya, M., & Erkan, D. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0775-8 · Cited by 25
“(23% on prophylaxis) Pengo, 2011 [37] Prospective observational Triple aPL-positive individuals (n = 104) 47 4.5 years 25 patients developed thrombosis ATIR 5.3% (64% on prophylaxis) Yelnik, 2017 [38] Prospective observational Asymptomatic aPL-positive individuals (n = 98) 78 13 years 28 patients…”
BackgroundInfluentialRelationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review
Bucci, T., Menichelli, D., Pignatelli, P., Triggiani, M., Violi, F., & Pastori, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181294 · Cited by 24
What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?
Arachchillage, D. J., & Laffan, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16431 · Cited by 26
“This may be infection; endothelial injury; inflammation; immunological or other non-immunological procoagulant factors such as hormonal therapy, surgery or immobility (Pengo et al., 2011) in interaction with the patient’s genetic constitution.”
BackgroundCerdà, P., Becattini, C., Iriarte, A., Cortés-Hernández, J., Corbella, X., & Riera‐Mestre, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.012 · Cited by 25
Pontara, E., Cattini, M. G., Cheng, C., Bison, E., Denas, G., & Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15199 · Cited by 23
Self-citationB cells in primary antiphospholipid syndrome: Review and remaining challenges
Dieudonné, Y., Guffroy, A., Poindron, V., Soulas-Sprauel, P., Martin, T., Korganow, A., & Gies, V. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102798 · Cited by 23
The Future of Antiphospholipid Antibody Testing
de Groot, P. G., & Urbanus, R. T. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304715 · Cited by 22
How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores
Oku, K., Amengual, O., Yasuda, S., & Atsumi, T. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0674-4 · Cited by 22
Bertin, D., Camoin‐Jau, L., Veit, V., Resseguier, N., Lambert, M., Buffet Delmas, P., Heim, X., Mège, J., Morange, P., & Bardin, N. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15518 · Cited by 21
Dos and don'ts in diagnosing antiphospholipid syndrome
Rand, J. H., & Wolgast, L. R. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.455.3806865 · Cited by 21
Risk of Thromboembolism in Patients with Immune Thrombocytopenia
(2015) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000185 · Cited by 22
“01) [86], while aPL-positive individuals did not benefit from aspirin for primary thrombosis prophylaxis [87,88].”
BackgroundSerrano, M., Martínez-Flores, J. A., Castro, M. J., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/641962 · Cited by 20
“8% [47].”
Erkan, D., Sciascia, S., Bertolaccini, M. L., Cohen, H., ANDRADE, D. C. O. D., Atsumi, T., Gerosa, M., Petri, M., Roubey, R. A. S., & Tektonidou, M. G. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01008-8 · Cited by 20
“Triple aPL positivity is the aPL phenotype that confers the highest risk of thrombosis [39].”
BackgroundNeuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management
Tayer-Shifman, O. E., Bingham, K. S., & Touma, Z. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00911-0 · Cited by 22
Guédon, A. F., Ricard, L., Laurent, C., MOREUIL, C. D., Urbanski, G., Deriaz, S., Gerotziafas, G., Elalamy, I., Audemard‐Verger, A., Chasset, F., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002881 · Cited by 21
Treatment of the antiphospholipid syndrome
Galli, M. (2013) · Autoimmunity Highlights · doi:10.1007/s13317-013-0056-5 · Cited by 38
Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome
Sciascia, S., & Bertolaccini, M. L. (2014) · Lupus · doi:10.1177/0961203314538332 · Cited by 20
Laboratory criteria for antiphospholipid syndrome: reply
Devreese, K. M. J., Ortel, T. L., Pengo, V., & de Laat, B. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14238 · Cited by 20
Self-citationFrodlund, M., Vikerfors, A., Grosso, G., Skogh, T., Wetterö, J., Elvin, K., Gunnarsson, I., Kastbom, A., Dahlström, Ö., Rönnelid, J., et al. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13180 · Cited by 20
Hu, C., Li, S., Xie, Z., You, H., Jiang, H., Shi, Y., Qi, W., Zhao, J., Wang, Q., Tian, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741369 · Cited by 20
Diagnosis and management of antiphospholipid syndrome
Heuser, C. C., & Branch, W. D. (2018) · doi:10.1002/9781119072980.ch31 · Cited by 20
Pavoni, V., Gianesello, L., & Horton, A. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02470-y · Cited by 19
“Re-testing after 3 months to ensure the reliability is recommended particularly in cases of an initial triple-positive test [39].”
BackgroundPrimary prevention in antiphospholipid antibody carriers
Bertero, M. (2012) · Lupus · doi:10.1177/0961203312445229 · Cited by 19
Recent advances in understanding antiphospholipid syndrome
Bertolaccini, M. L., & Sanna, G. (2016) · F1000Research · doi:10.12688/f1000research.9717.1 · Cited by 20
Gris, J., Cyprien, F., Bouvier, S., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1333146 · Cited by 19
“Triple positivity for aPlAbs (Ruffatti et al. 2010; Pengo et al. 2011; Ruffatti et al. 2011), restricted to IgG isotypes, was detected in 7.3% of the patients.”
InfluentialNigolian, H., Ribi, C., Courvoisier, D. S., Pagano, S., Alvarez, M., Trendelenburg, M., Huynh‐Do, U., Vuilleumier, N., Dayer, J., Chizzolini, C., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez306 · Cited by 19
Thrombocytopenic syndromes in pregnancy
Yan, M. T. S., Malinowski, A. K., & Shehata, N. (2015) · Obstetric Medicine · doi:10.1177/1753495x15601937 · Cited by 19
“In contrast, screening for aPL has been advocated as thrombocytopenia occurs in 10–20% patients with aPL,(10,11) and there is potentially a risk of thrombosis in asymptomatic carriers of aPL (5%/year).(12) Accordingly, a careful selection of pregnant patients with thrombocytopenia to screen for aPL, i.”
BackgroundAntiphospholipid antibody syndrome
Whitaker, K. L. (2017) · JAAPA · doi:10.1097/01.jaa.0000526771.67820.59 · Cited by 19
Zhang, Y., Su, Y., Guo, H., Wang, L., Li, A., Wang, C., Zhang, J., & Qiao, R. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.12.007 · Cited by 19
Evolution of Antiphospholipid Syndrome
Arachchillage, D. J., & Pericleous, C. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760333 · Cited by 21
Iwaniec, T., Kaczor, M. P., Celińska‐Löwenhoff, M., Polański, S., & Musiał, J. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3259 · Cited by 18
The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome
da Silva Saraiva, S., de Moraes Mazetto, B., Quinteiro Tobaldine, L., Pereira Colella, M., Vinícius De Paula, E., Annichinno‐Bizzachi, J., & Andrade Orsi, F. (2017) · American Journal of Hematology · doi:10.1002/ajh.24875 · Cited by 18
“This finding was not expected because previous clinical studies have shown that TP confers higher risk for the development of thrombosis and recurrent thrombotic events.(4,22,23) We believe that the risk of thrombosis in APS may not be attributed solely to the aPL profile.”
ResultThrombotic risk factors in patients with antiphospholipid syndrome: a single center experience
Abu-Zeinah, G. F., Oromendia, C., & DeSancho, M. T. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01836-7 · Cited by 16
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Laecke, S. V., Nagler, E., & Vanholder, R. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1410247 · Cited by 18
Kremers, R., Wahl, D. G., Zuily, S., Ninivaggi, M., Chayouâ, W., Regnault, V., Musiał, J., de Groot, P. G., Devreese, K. M. J., & de Laat, B. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.05.008 · Cited by 17
Can complement activation be the missing link in antiphospholipid syndrome?
Venturelli, V., Maranini, B., Tohidi‐Esfahani, I., Isenberg, D. A., Cohen, H., & Efthymiou, M. (2024) · Lara D. Veeken · doi:10.1093/rheumatology/keae178 · Cited by 17
Wolgast, L. R., Arslan, A. A., Wu, X. ‐., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13699 · Cited by 17
Self-citationTripodi, A., Scalambrino, E., Chantarangkul, V., Paoletti, O., Clerici, M., Novembrino, C., Boscolo-Anzoletti, M., Peyvandi, F., & Testa, S. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.001 · Cited by 17
Self-citationPablo, R. Q., Muñoz, P., López‐Hoyos, M., Calvo-Río, V., Riancho‐Zarrabeitia, L., & Martínez-Taboada, V. M. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08862-5 · Cited by 18
Celińska‐Löwenhoff, M., Ząbczyk, M., Iwaniec, T., Plens, K., Musiał, J., & Undas, A. (2018) · Rheumatology · doi:10.1093/rheumatology/key089 · Cited by 17
Pontara, E., Bison, E., Cattini, M. G., Tonello, M., Denas, G., & Pengo, V. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.06.033 · Cited by 16
Self-citationVenous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind
Silvariño, R., Danza, Ã., Mérola, V., Bérez, A., Méndez, E., Espinosa, G., & Cervera, R. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.05.002 · Cited by 18
Clinical utility of automated chemiluminescent antiphospholipid antibody assay
Iwaniec, T., Kaczor, M. P., Celińska‐Löwenhoff, M., Polański, S., & Musiał, J. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.08.021 · Cited by 16
Metadata
- Authors
- Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., Bison, E., Denas, G., Banzato, A., Padayattil Jose, S., & Iliceto, S.
- Affiliations
- Departments of Clinical Cardiology and
- University of Padua (IT)
- University of Bologna (IT)
- District Hospital, Cremona, Italy;
- University of Perugia (IT)
- University of Cagliari (IT)
- Transfusion Medicine, District Hospital, Merate, Italy; and
- Santa Maria Nuova Hospital (IT)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-10-27
- Volume
- 118
- Issue
- 17
- Pages
- 4714-4718
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1975074770
- Cited by
- 468
- References
- 28
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 35 · 2023: 36 · 2022: 18 · 2021: 41 · 2020: 46 · 2019: 42 · 2018: 39 · 2017: 38 · 2016: 29 · 2015: 23 · 2014: 33 · 2013: 28 · 2012: 28
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- antiphospholipid antibodies, thromboembolic events, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, triple positivity, venous thromboembolism, aspirin, primary thromboprophylaxis, risk factors, male sex, incidence
- MeSH terms
- Adolescent, Adult, Aged, Disease Susceptibility, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Thromboembolism, Incidence, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Early Diagnosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
